HC Wainwright Reaffirms “Buy” Rating for Gossamer Bio (NASDAQ:GOSS)

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports.

Separately, Weiss Ratings downgraded Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.20.

Gossamer Bio Stock Up 41.2%

Shares of GOSS traded up $0.06 on Monday, reaching $0.19. The stock had a trading volume of 225,158,015 shares, compared to its average volume of 15,731,231. The firm has a market capitalization of $45.06 million, a PE ratio of -0.24 and a beta of 2.04. The firm has a 50-day moving average of $0.18 and a 200 day moving average of $0.81. Gossamer Bio has a twelve month low of $0.11 and a twelve month high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $16.95 million during the quarter, compared to analysts’ expectations of $4.67 million. On average, sell-side analysts anticipate that Gossamer Bio will post -0.37 earnings per share for the current fiscal year.

Institutional Trading of Gossamer Bio

A number of large investors have recently made changes to their positions in GOSS. Vanguard Group Inc. raised its stake in Gossamer Bio by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock valued at $31,586,000 after purchasing an additional 598,981 shares during the last quarter. Kalehua Capital Management LLC acquired a new stake in shares of Gossamer Bio during the 1st quarter worth about $3,363,000. State Street Corp grew its holdings in shares of Gossamer Bio by 139.7% during the fourth quarter. State Street Corp now owns 9,310,969 shares of the company’s stock worth $28,864,000 after buying an additional 5,427,302 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Gossamer Bio by 3.9% during the fourth quarter. Geode Capital Management LLC now owns 4,872,714 shares of the company’s stock worth $15,109,000 after buying an additional 183,183 shares in the last quarter. Finally, Corient Private Wealth LLC raised its position in shares of Gossamer Bio by 19,123.7% in the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock valued at $11,922,000 after buying an additional 3,825,879 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.